Long-term effects of doxazosin, finasteride, and combination therapy on quality of life in men with benign prostatic hyperplasia
Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW. J Urol. 2013 Jan 25. pii: S0022-5347(13)00097-9. doi: 10.1016/j.juro.2013.01.061. [Epub ahead of print]

Source

Social & Scientific Systems, Inc., Silver Spring, MD. Electronic address: cfwu@s-3.com.

Abstract

PURPOSE:

To examine the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia (BPH) on quality of life (QoL) assessed by a general (the Medical Outcomes Study Short-Form-36 [MOS-SF-36]) and two disease-specific instruments (the BPH Impact Index [BII] and the International Prostate Symptom Score [IPSS]-QoL) over 4 years.

MATERIALS AND METHODS:

The Medical Therapy of Prostatic Symptoms (MTOPS) Study was a multi-center, randomized, double-blind, placebo-controlled clinical trial with a primary outcome of time-to-BPH progression. Change in QoL was a secondary outcome. A total of 2,872 men enrolled in the MTOPS Study who had three baseline QoL measures and at least one follow-up measure by any of the QoL instruments were analyzed.

RESULTS:

Compared with men assigned to placebo, men assigned to doxazosin and combination experienced a statistically significant improvement in the BII at year 4. Men assigned to each of the drug groups also experienced a significant improvement in the IPSS-QoL compared with those assigned to placebo. Considering longitudinal changes over 4 years, a significant improvement in BII and IPSS-QoL scores was observed in men assigned to the drug groups compared with those assigned to placebo. However, there were no significant differences for the MOS-SF-36 subscales and summary scores when drug groups were compared with the placebo group.

CONCLUSIONS:

QoL of men treated with doxazosin, finasteride, and the drugs combined generally improved when assessed with the BII and the IPSS-QoL compared with those treated with placebo. QoL did not show improvement when measured by the MOS-SF-36.